NCT06055621 2026-03-13
VEN-R DASA
Institut Paoli-Calmettes
Phase 2 Recruiting
Clinical Trials
10 trialsNCT03297606 2026-03-04
CAPTUR
Canadian Cancer Trials Group
Phase 2 Recruiting
NCT02559778 2026-02-20
PEDS-PLAN
Milton S. Hershey Medical Center
Phase 2 Recruiting
NCT05007873 2026-02-18
ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06533748 2026-02-12
Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma
St. Jude Children's Research Hospital
Phase 2 Recruiting
NCT04626024 2025-12-19
TOKIN
Baylor College of Medicine
Phase 2 Recruiting
NCT04838041 2025-07-30
Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
Medical College of Wisconsin
Phase 2 Recruiting
NCT04925648 2025-05-15
PICASSO
St Vincent's Hospital, Sydney
Phase 2 Recruiting
NCT06355037 2024-07-08
Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer
Fudan University
Phase 2 Recruiting
NCT05725200 2023-02-21
EVIDENT
Oslo University Hospital
Phase 2 Recruiting